Showing 1 - 10 of 232
This paper aims at characterizing the dynamics of R&D competition within the pharmaceutical domain, focusing on the role of patent disclosure, the extent of uncertainty, and role of scientific advances. Following the empirical literature in the economics of innovation, we employ patents as a...
Persistent link: https://www.econbiz.de/10011265771
During the last thirty years health care expenditure (HCE) has been growing much more rapidly than GDP in all OECD countries posing increasing concern on the long-term sustainability of current trends. Against this background, we look at the determinants of HCE in European countries, explicitly...
Persistent link: https://www.econbiz.de/10011265783
This paper aims at characterizing the dynamics of R&D competition within the pharmaceutical domain, focusing on the role of patent disclosure, the extent of uncertainty, and role of scientific advances. Following the empirical literature in the economics of innovation, we employ patents as a...
Persistent link: https://www.econbiz.de/10005245144
During the last thirty years health care expenditure (HCE) has been growing much more rapidly than GDP in all OECD countries posing increasing concern on the long-term sustainability of current trends. Against this background, we look at the determinants of HCE in European countries, explicitly...
Persistent link: https://www.econbiz.de/10005078989
Persistent link: https://www.econbiz.de/10003897672
Persistent link: https://www.econbiz.de/10009658375
Persistent link: https://www.econbiz.de/10011477734
Persistent link: https://www.econbiz.de/10011590738
During the last 30 years, health care expenditure (HCE) has been growing much more rapidly than GDP in OECD countries. In this paper, we review the determinants of HCE dynamics in Europe, taking into account the role of income, aging population, technological progress, female labor...
Persistent link: https://www.econbiz.de/10010993849
We build a cumulative innovation model in which both success and failure provide valuable information for future research. To test this learning mechanism, we use a dataset covering outcomes of world-wide R&D projects in the pharmaceutical industry, and proxy knowledge flows with forward...
Persistent link: https://www.econbiz.de/10010925514